These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27408122)

  • 21. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
    Khanam S; Rajendra P; Khanna N; Swaminathan S
    BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.
    Anderson KB; Gibbons RV; Edelman R; Eckels KH; Putnak RJ; Innis BL; Sun W
    J Infect Dis; 2011 Aug; 204(3):442-50. PubMed ID: 21742844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Saville M; Lang J
    Hum Vaccin; 2010 Sep; 6(9):. PubMed ID: 20861669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys.
    Yoshimura M; Shinmura Y; Takagi S; Kameyama K; Sonoda K; Koide F; Yoksan S; Kimachi K
    Heliyon; 2020 Jul; 6(7):e04506. PubMed ID: 32760828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tetravalent dengue vaccine development].
    Guy B; Saville M; Lang J
    Virologie (Montrouge); 2010 Oct; 14(5):311-321. PubMed ID: 36151693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines.
    Bonaldo MC; Caufour PS; Freire MS; Galler R
    Mem Inst Oswaldo Cruz; 2000; 95 Suppl 1():215-23. PubMed ID: 11142718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.
    White LJ; Sariol CA; Mattocks MD; Wahala M P B W; Yingsiwaphat V; Collier ML; Whitley J; Mikkelsen R; Rodriguez IV; Martinez MI; de Silva A; Johnston RE
    J Virol; 2013 Mar; 87(6):3409-24. PubMed ID: 23302884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell and memory B cell responses in tetravalent DNA, tetravalent inactivated and tetravalent live-attenuated prime-boost dengue vaccines in rhesus macaques.
    Sun P; Jani V; Johnson A; Cheng Y; Nagabhushana N; Williams M; Morrison BJ; Defang G
    Vaccine; 2021 Dec; 39(51):7510-7520. PubMed ID: 34823910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
    Moris P; Bauer KM; Currier JR; Friberg H; Eckels KH; Esquilin IO; Gibbons RV; Innis BL; Jarman RG; Simasathien S; Sun P; Thomas SJ; Watanaveeradej V
    Hum Vaccin Immunother; 2019; 15(9):2090-2105. PubMed ID: 30829100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of sanofi pasteur tetravalent dengue vaccine.
    Guy B
    J Clin Virol; 2009 Oct; 46 Suppl 2():S16-9. PubMed ID: 19800561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Developments in Recombinant Protein-Based Dengue Vaccines.
    Tripathi NK; Shrivastava A
    Front Immunol; 2018; 9():1919. PubMed ID: 30190720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
    Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.
    Hou J; Ye W; Chen J
    Front Immunol; 2022; 13():840104. PubMed ID: 35281026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
    Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
    Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.